

分子標的医学研究センター

論文

A 欧文

A-a

1. Kurata R, Kumagai A, Cui X, Harada M, Nagai J, Yoshida Y, Ozaki KI, Tanaka Y, Yonezawa T: Establishment of Novel Reporter Cells Stably Maintaining Transcription Factor-driven Human Secreted Alkaline Phosphatase Expression. *Curr Pharm Biotechnol* 19(3): 224-231, 2018 (IF: 1.819) *○◇
2. Mosaddeque F, Mizukami S, Kamel MG, Teklemichael AA, Dat TV, Mizuta S, Toan DV, Ahmed AM, Vuong NL, Elhady MT, Giang HTN, Dang TN, Fukuda M, Huynh LK, Tanaka Y, Egan TJ, Kaneko O, Huy NT, Hirayama K: Prediction Model for Antimalarial Activities of Hemozoin Inhibitors by Using Physicochemical Properties. *Antimicrob Agents Chemother* 62(5) : e02424-17, 2018 (IF: 4.255) *◇
3. El-Darawish Y, Li W, Yamanishi K, Pencheva M, Oka N, Yamanishi H, Matsuyama T, Tanaka Y, Minato N, Okamura H: Frontline Science: IL-18 primes murine NK cells for proliferation by promoting protein synthesis, survival, and autophagy. *J Leukoc Biol* 104(2): 253-264, 2018 (IF: 4.224) *◇
4. Tanaka Y, Murata-Hirai K, Iwasaki M, Matsumoto K, Hayashi K, Kumagai A, Nada MH, Wang H, Kobayashi H, Kamitakahara H, Okamura H, Sugie T, Minato N, Toi M, Morita CT: Expansion of human $\gamma\delta$ T cells for adoptive immunotherapy using a bisphosphonate prodrug. *Cancer Sci* 109(3): 587-599, 2018 (IF: 4.372) *◇
5. Sugie T, Suzuki E, Yamauchi A, Yamagami K, Masuda N, Gondo N, Sumi E, Ikeda T, Tada H, Uozumi R, Kanao S, Tanaka Y, Hamazaki Y, Minato N, Toi M: Combined effects of neoadjuvant letrozole and zoledronic acid on $\gamma\delta$ T cells in postmenopausal women with early-stage breast cancer. *Breast* 38:114-119, 2018 (IF: 2.951) *◇
6. Senju H, Kumagai A, Nakamura Y, Yamaguchi H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura H, Tanaka Y, Mukae H: Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy. *Int J Biol Sci* 14(3): 331-340, 2018 (IF: 4.057) *◇
7. Koga T, Sato S, Miyamoto J, Hagimori N, Kawazoe Y, Arinaga K, Fukushima C, Yamamoto H, Kawakami A: Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial. *Trials* (<https://trialsjournal.biomedcentral.com>) 19(1): 715, 2018 (IF: 2.067) *
8. Endo Y, Koga T, Eguchi M, Okamoto M, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kawakami A: Utility of power Doppler ultrasonography for detecting forefoot bursae in early rheumatoid arthritis: A case report. *Medicine (Baltimore)* (<https://www.medicinejournal.co.uk>) 97(51): e13295, 2018 (IF: 2.028) *
9. Migita K, Horai Y, Kozuru H, Koga T, Abiru S, Yamasaki K, Komori A, Fujita Y, Asano T, Sato S, Suzuki E, Matsuoka N, Kobayashi H, Watanabe H, Naganuma A, Naeshiro N, Yoshizawa K, Ohta H, Sakai H, Shimada M, Nishimura H, Tomizawa M, Ario K, Yamashita H, Kamitsukasa H, Kohno H, Nakamura M, Furukawa H, Takahashi A, Kawakami A, Ohira H, Yastuhashi H: Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis. *Medicine (Baltimore)* (<https://www.medicinejournal.co.uk>) 97(50): e13450, 2018 (IF: 2.028) *
10. Yashiro M, Furukawa H, Asano T, Sato S, Kobayashi H, Watanabe H, Suzuki E, Nakamura T, Koga T, Shimizu T, Umeda M, Nonaka F, Ueki Y, Eguchi K, Kawakami A, Migita K: Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still's disease. *Medicine (Baltimore)* (<https://www.medicinejournal.co.uk>) 97(49): e13394, 2018 (IF: 2.028) *
11. Sato S, Fujita Y, Shigemura T, Matoba H, Agematsu K, Sumichika Y, Yashiro M, Ono A, Kawasaki Y, Kobayashi H, Watanabe H, Koga T, Kawakami A, Migita K: Juvenile onset autoinflammatory disease due to a novel mutation in TNFAIP3 (A20). *Arthritis Res Ther* (<https://arthritis-research.biomedcentral.com>) 20(1): 274, 2018 (IF: 4.269) *
12. Endo Y, Koga T, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Agematsu K, Yachie A, Masumoto J, Migita K, Kawakami A: Musculoskeletal manifestations occur predominantly in patients with later-onset familial Mediterranean fever: Data from a multicenter, prospective national cohort study in Japan. *Arthritis Res Ther* (<https://arthritis-research.biomedcentral.com>) 20(1): 257, 2018 (IF: 4.269) *
13. Koga T, Matoba M, Sato T, Koike Y, Endo Y, Sumiyoshi R, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kawakami A: Evaluation of circulating invariant T cells before and after IL-17 inhibitor treatment in a patient with psoriatic arthritis. *Clin Immunol* 197: 107-109, 2018 (IF: 3.557) *
14. Furuya MY, Asano T, Sumichika Y, Sato S, Kobayashi H, Watanabe H, Suzuki E, Kozuru H, Yastuhashi H, Koga T, Ohira H, Sekine H, Kawakami A, Migita K.: Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils. *Arthritis Res Ther* (<https://arthritis-research.biomedcentral.com>) 20(1): 196, 2018 (IF: 4.269) *

15. Koga T, Umeda M, Endo Y, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Murakami N, Kitajima M, Kawakami A: Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study. *Int J Rheum* 21(6): 1287-1292, 2018 (IF: 2.423) *
16. Koga T, Migita K, Sato T, Sato S, Umeda M, Nonaka F, Fukui S, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Ueki Y, Masumoto J, Agematsu K, Yachie A, Yoshiura KI, Eguchi K, Kawakami A: MicroRNA-204-3p inhibits lipopolysaccharide-induced cytokines in familial Mediterranean fever via the phosphoinositide 3-kinase γ pathway. *Rheumatology (Oxford)* 57(4): 718-726, 2018 (IF: 5.245) *
17. Mizuta S, Makau JN, Kitagawa A, Kitamura K, Otaki H, Nishi K, Watanabe K: Synthesis of trifluoromethyl- α,β -unsaturated lactones and pyrazolinones and discovery of influenza virus polymerase inhibitors. *ChemMedChem* 13 (22): 2390-2399, 2018 (IF: 3.009) *
18. Taguchi Y, Lu L, Marrero-Winkens C, Otaki H, Nishida N, Schatzl HM: Disulfide-crosslink scanning reveals prion-induced conformational changes and prion strain-specific structures of the pathological prion protein PrP^{Sc}. *J Biol Chem* 293 (33): 12730-12740, 2018 (IF: 4.011) *
19. Farhana Mosaddeque, Shusaku Mizukami, Mohamed Goma Kamel, Awet Teklemichael, Truong Van Dat, Satoshi Mizuta, Dinh Van Toan, Ali Mahmoud Ahmed, Nguyen Lam Vuong, Mohamed Tamer Elhady, Hoang Thi Nam Giang, Tran Ngoc Dang, Michiko Fukuda, Lam K. Huynh, Yoshimasa Tanaka, Timothy J. Egan, Osamu Kaneko, Nguyen Tien Huy, Kenji Hirayama: Prediction model for anti-malarial activities of hemozoin inhibitors using physicochemical properties. *Antimicrob Agents Chemother* 62(5): e02424-17, 2018 (IF: 4.302) *
20. T. Ishikawa, S. Mizuta, O. Kaneko, K. Yahata: Fragment Molecular Orbital Study of the Interaction between Sarco/ Endoplasmic Reticulum Ca²⁺-ATPase and its Inhibitor Thapsigargin toward Anti-Malarial Development. *J Phys Chem B* 122(33): 7970-7977, 2018 (IF: 3.146) *
21. S. Mizuta, J. N. Makaanu, A. Kitagawa, K. Kitamura, H. Otaki, K. Nishi, K. Watanabe: Synthesis of trifluoromethyl- α,β -unsaturated lactones and discovery of influenza virus polymerase inhibitors. *Chem Med Chem* 13: 2390-2399, 2018 (IF: 3.225) *
22. Kaneko M, Do LP, Doan YH, Nakagomi T, Gauchan P, Agbemabiese CA, Dang AD, Nakagomi O: Porcine-like G3P[6] and G4P[6] rotavirus A strains detected from children with diarrhoea in Vietnam. *Arch Virol* 163(8): 2261-2263, 2018 (IF: 2.160) *
23. Kikuchi W, Nakagomi T, Gauchan P, Agbemabiese CA, Noguchi A, Nakagomi O, Takahashi T: Detection in Japan of an equine-like G3P[8] reassortant rotavirus A strain that is highly homologous to European strains across all genome segments. *Arch Virol* 163(3): 791-794, 2018 (IF: 2.160) *

A-b

1. Koga T, Sumiyoshi R, Kawakami A, Yoshizaki K.: A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease. *Mod Rheumatol* :1-9, 2018 (IF: 1.955) *

B 邦文

B-b

1. 田中義正: アカデミア創薬: NK細胞療法. *プレジジョンメディシン* 1 (3): 72-79, 2018
2. 田中義正, 藤原雄介: アカデミア創薬: 企業導出と英語. *アグリバイオ* 2 (12): 59-68, 2018
3. 田中義正: V γ 2V δ 2 陽性 $\gamma\delta$ 型 T細胞療法. *プレジジョンメディシン* 1 (2): 67-70, 2018
4. 田中義正, 本田詩乃, 日高葵, 西川恵, 武田弘資: アカデミア創薬: 海洋微生物抽出物ライブラリー. *アグリバイオ* 2 (10): 69-78, 2018
5. 田中義正, 藤原雄介: アカデミア創薬: 基礎と臨床の連携. *アグリバイオ* 2 (9): 47-56, 2018
6. 田中義正, 藤原雄介: アカデミア創薬のパラダイムシフト. *アグリバイオ* 2 (8): 81-90, 2018
7. 田中義正: $\gamma\delta$ 型 T細胞を用いたがん免疫療法. *アレルギーの臨床* 38(7): 94-101, 2018
8. 田中義正: $\gamma\delta$ 型 T細胞とがん免疫療法. *地域ケアリング* 20(6): 74-80, 2018
9. 田中義正, 藤原雄介: アカデミア創薬: 創薬のパラダイムシフト. *アグリバイオ* 2 (6): 63-72, 2018
10. 田中義正: がん免疫療法と非 RI 細胞障害能測定法. *アレルギーの臨床* 38(5): 84-90, 2018
11. 田中義正: PD-1 免疫チェックポイント阻害剤を用いたがん免疫療法. *アレルギーの臨床* 38(4): 74-83, 2018
12. 田中義正: PD-1 免疫チェックポイントとがん免疫療法. *アグリバイオ* 2 (3): 79-88, 2018

13. 田中義正: 免疫チェックポイント併用療法. アレルギーの臨床 38(2): 82-91, 2018
14. 古賀智裕, 川上 純: 【新たに追加された指定難病キャッスルマン病を理解する】 キャッスルマン病に対する新たな治療法の開発(解説/特集): 成人病と生活習慣病 (1347-0418)48 巻 12 号 Page1356-1359(2018.12)
15. 古賀智裕, 川上 純: 【新たに追加された指定難病キャッスルマン病を理解する】 キャッスルマン病の病因・病態: 成人病と生活習慣病 (1347-0418)48 巻 12 号 Page1309-1313(2018.12)
16. 古賀智裕, 川上 純: 自己炎症性疾患の診断と治療: 臨床免疫・アレルギー科 (1881-1930)70 巻 6 号 Page618-622(2018.12)
17. 古賀智裕, 川上 純: 【IL-6 阻害療法の基礎と臨床】 自己炎症性疾患におけるトシリズマブの有用性と問題点: リウマチ科 (0915-227X)60 巻 2 号 Page169-174(2018.08)

B-d

1. 大滝大樹: 拡張アンサンブル法を用いたタンパク質の構造変化と変異が及ぼす影響の解析, 東京大学情報基盤センター スーパーコンピューティングニュース 20, Special Issue 1, pp. 3-9, 2018

研究業績集計表

教室等名: 分子標的医学研究センター

論文数一覧

	A-a	A-b	A-c	A-d	A-e	合計	SCI	B-a	B-b	B-c	B-d	B-e	合計	総計
2018	23	1	0	0	0	24	24	0	17	0	1	0	18	42

学会発表数一覧

	A-a	A-b		合計	B-a	B-b		合計	総計
		シンポジウム	学会			シンポジウム	学会		
2018	4	0	6	10	7	2	13	22	32

論文総数に係る教員生産係数一覧

	$\frac{\text{欧文論文総数}}{\text{論文総数}}$	教員生産係数 (欧文論文)	$\frac{\text{SCI掲載論文数}}{\text{欧文論文総数}}$	教員生産係数 (SCI掲載論文)
2018	0.571	3.429	1	3.429

Impact factor 値一覧

	Impact factor	教員当たり Impact factor	論文当たり Impact factor
2018	77.829	11.118	3.243